NO20043707L - Nye immuno effektor forbindelser - Google Patents
Nye immuno effektor forbindelserInfo
- Publication number
- NO20043707L NO20043707L NO20043707A NO20043707A NO20043707L NO 20043707 L NO20043707 L NO 20043707L NO 20043707 A NO20043707 A NO 20043707A NO 20043707 A NO20043707 A NO 20043707A NO 20043707 L NO20043707 L NO 20043707L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- effector compounds
- antigen
- new immuno
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000012636 effector Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- SXSXOQFGUZXAEK-SXTMZTKSSA-N N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O SXSXOQFGUZXAEK-SXTMZTKSSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/003580 WO2003065806A1 (en) | 2002-02-04 | 2002-02-04 | New immunoeffector compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043707L true NO20043707L (no) | 2004-09-03 |
Family
ID=27732075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043707A NO20043707L (no) | 2002-02-04 | 2004-09-03 | Nye immuno effektor forbindelser |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1482795B1 (no) |
| JP (1) | JP2005516980A (no) |
| KR (1) | KR100885008B1 (no) |
| CN (1) | CN1301134C (no) |
| AT (1) | ATE447844T1 (no) |
| AU (1) | AU2002253909B2 (no) |
| BR (1) | BR0215588A (no) |
| CA (1) | CA2474398A1 (no) |
| CY (1) | CY1109692T1 (no) |
| CZ (1) | CZ2004862A3 (no) |
| DE (1) | DE60234386D1 (no) |
| DK (1) | DK1482795T3 (no) |
| ES (1) | ES2336080T3 (no) |
| HU (1) | HUP0500539A2 (no) |
| IL (1) | IL163304A (no) |
| MX (1) | MXPA04008559A (no) |
| NO (1) | NO20043707L (no) |
| PT (1) | PT1482795E (no) |
| WO (1) | WO2003065806A1 (no) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1482955B1 (en) * | 2002-02-04 | 2013-12-25 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| NZ569168A (en) | 2005-12-22 | 2012-02-24 | Glaxosmithkline Biolog Sa | Streptococcus pneumoniae polysaccharide conjugate vaccine comprising 19F-DT conjugate |
| ES2539042T3 (es) | 2006-06-02 | 2015-06-25 | Glaxosmithkline Biologicals S.A. | Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia |
| KR101579947B1 (ko) | 2007-06-26 | 2015-12-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신 |
| WO2009037438A1 (en) | 2007-09-17 | 2009-03-26 | Oncomethylome Sciences Sa | Improved detection of mage-a expression |
| MX2011009597A (es) | 2009-03-17 | 2012-05-29 | Glaxosmithkline Biolog Sa | Deteccion mejorada de la expresion del gen. |
| GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| GB2599572B (en) * | 2019-05-20 | 2023-09-20 | Soligenix Inc | Compositions and methods of manufacturing trivalent filovirus vaccines |
| US20220273789A1 (en) | 2019-07-21 | 2022-09-01 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
| US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987237A (en) * | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US5607698A (en) * | 1988-08-04 | 1997-03-04 | Ciba-Geigy Corporation | Method of preserving ophthalmic solution and compositions therefor |
| US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6013640A (en) | 1998-08-21 | 2000-01-11 | Ribi Immunochem Research, Inc. | Phosphoglycolipid and methods for its use |
| US6699846B2 (en) | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
| ATE321063T1 (de) * | 2000-08-04 | 2006-04-15 | Corixa Corp | Neue immunoeffectorverbindungen |
| EP1482955B1 (en) * | 2002-02-04 | 2013-12-25 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
-
2002
- 2002-02-04 KR KR1020047011984A patent/KR100885008B1/ko active IP Right Grant
- 2002-02-04 BR BR0215588-5A patent/BR0215588A/pt not_active IP Right Cessation
- 2002-02-04 AT AT02723106T patent/ATE447844T1/de active
- 2002-02-04 AU AU2002253909A patent/AU2002253909B2/en not_active Expired
- 2002-02-04 DE DE60234386T patent/DE60234386D1/de not_active Expired - Lifetime
- 2002-02-04 MX MXPA04008559A patent/MXPA04008559A/es active IP Right Grant
- 2002-02-04 PT PT02723106T patent/PT1482795E/pt unknown
- 2002-02-04 WO PCT/US2002/003580 patent/WO2003065806A1/en active Application Filing
- 2002-02-04 EP EP02723106A patent/EP1482795B1/en not_active Expired - Lifetime
- 2002-02-04 CA CA002474398A patent/CA2474398A1/en not_active Abandoned
- 2002-02-04 DK DK02723106.7T patent/DK1482795T3/da active
- 2002-02-04 HU HU0500539A patent/HUP0500539A2/hu unknown
- 2002-02-04 JP JP2003565242A patent/JP2005516980A/ja active Pending
- 2002-02-04 CN CNB028283643A patent/CN1301134C/zh not_active Expired - Lifetime
- 2002-02-04 ES ES02723106T patent/ES2336080T3/es not_active Expired - Lifetime
- 2002-02-04 CZ CZ2004862A patent/CZ2004862A3/cs unknown
-
2004
- 2004-08-01 IL IL163304A patent/IL163304A/en active IP Right Grant
- 2004-09-03 NO NO20043707A patent/NO20043707L/no not_active Application Discontinuation
-
2009
- 2009-12-30 CY CY20091101354T patent/CY1109692T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04008559A (es) | 2004-12-06 |
| EP1482795A4 (en) | 2006-08-09 |
| KR20040083433A (ko) | 2004-10-01 |
| ATE447844T1 (de) | 2009-11-15 |
| CA2474398A1 (en) | 2003-08-14 |
| CZ2004862A3 (cs) | 2005-01-12 |
| ES2336080T3 (es) | 2010-04-08 |
| WO2003065806A1 (en) | 2003-08-14 |
| HUP0500539A2 (en) | 2006-09-28 |
| CY1109692T1 (el) | 2014-08-13 |
| PT1482795E (pt) | 2010-02-09 |
| IL163304A (en) | 2010-11-30 |
| AU2002253909A1 (en) | 2003-09-02 |
| BR0215588A (pt) | 2005-03-22 |
| EP1482795A1 (en) | 2004-12-08 |
| CN1301134C (zh) | 2007-02-21 |
| DK1482795T3 (da) | 2010-02-01 |
| DE60234386D1 (de) | 2009-12-24 |
| EP1482795B1 (en) | 2009-11-11 |
| CN1622754A (zh) | 2005-06-01 |
| KR100885008B1 (ko) | 2009-02-20 |
| AU2002253909B2 (en) | 2008-06-05 |
| JP2005516980A (ja) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE321063T1 (de) | Neue immunoeffectorverbindungen | |
| CY1109692T1 (el) | Νεες ανοσοδραστικες συνθεσεις | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1113190T1 (el) | Μεθοδος αγωγης της αιμολυτικης νοσου | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| TR200103018T2 (tr) | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| NO20072526L (no) | Halvfaste C-klasse immunstimulerende oligonukleotider | |
| NO20060979L (no) | Nye tricykliske nukleosider eller nukleotider som terapeutiske midler | |
| TW200633719A (en) | Glycoconjugate vaccines containing peptidoglycan | |
| TW200512457A (en) | Method of diagnosing SARS corona virus infection | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| MXPA05014016A (es) | Proteinas portadoras para vacunas. | |
| MEP32608A (en) | Antibodies to opgl | |
| CY1114243T1 (el) | Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων | |
| IN2008CN05409A (no) | ||
| BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
| NO932102D0 (no) | Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen | |
| NO20065671L (no) | Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier. | |
| UA89800C2 (en) | Acylated nonadepsipeptides used as lysobactin derivatives | |
| DE602005007177D1 (de) | Komplexe mit adjuvanter wirkung | |
| SG147465A1 (en) | Vaccine | |
| EA200870263A1 (ru) | Внутривенный способ лечения вирусной инфекции | |
| DE502004010393D1 (de) | Leukozytenstimulations-Matrix | |
| DE602004023311D1 (de) | Antigen-zufuhrsystem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |